Algeta ASA : Algeta schedules first quarter 2013 results presentation, webcast and conference call

Algeta ASA : Algeta schedules first quarter 2013 results presentation, webcast
                             and conference call

Oslo, Norway, 7 May 2013 - Algeta ASA (OSE: ALGETA), a company focused on the
development of novel targeted cancer therapeutics, will announce its first
quarter 2013 results on Wednesday, 15 May 2013. A presentation by Algeta's
senior management team to investors, analysts and the press will take place in
Oslo at 10:00 CET.

The presentation  will  also be  webcast  live  and can  be  accessed  through 
www.algeta.com where questions can also be submitted during the presentation.

The presentation will take place at 10:00 CET at:

Shippingklubben
Haakon VIIs gate 1
0161 Oslo
Norway.

Algeta's senior management will also host an international conference call  at 
14:30 CET/08:30 Eastern Time (US) (details below).

To participate  in the  conference call,  please dial  the appropriate  number 
below five minutes prior to the call:

US: +1877423 0830
UK: +4420 7153 9154
Norway: +47 21 06 61 13
Sweden: +468-506443 86
Denmark: +45 32 71 42 62
Switzerland: +41 44580 65 22

Participant pin code: 281404#



To access the replay, please dial:

US: +1877679 2989
UK: +44 20 3364 5196
Norway: +47 23 50 02 03
Sweden: +46 8-505564 73

Conference reference: 346423#

A  replay  version  of  the  conference   call  will  also  be  available   at 
www.algeta.com.

The results report and the presentation will be available at www.algeta.com in
the Investors section from 07:00 CET.

                                     ###

For further information, please contact:

Mike Booth / Renate Birkeli          +47 23 00 67 32
Communications & Corporate Affairs   ir@algeta.com
Media enquiries:
Mark Swallow                         +44 207 638 9571
Citigate Dewe Rogerson               mark.swallow@citigatedr.co.uk
Knut Ekern                           +47 22 04 82 00
Gambit Hill & Knowlton               knut.ekern@hkstrategies.com
Kari Watson                          +1 781 235 3060
MacDougall Biomedical Communications kwatson@macbiocom.com 
US investor enquiries:
Tricia Swanson                       +1 646 378 2953
The Trout Group                      tswanson@troutgroup.com

About Algeta

Algeta is a company focused on developing novel targeted therapies for
patients with cancer based on its alpha-pharmaceutical platform. The Company
is headquartered in Oslo, Norway, and has a US subsidiary, Algeta US, LLC,
based in Cambridge, MA performing commercial marketing operations in the US.
Algeta is listed on the Oslo Stock Exchange (Ticker: ALGETA). For more
information please visit www.algeta.com.

This information is subject of the disclosure requirements pursuant to section
5-12 of the Norwegian Securities Trading Act.
Press release

------------------------------------------------------------------------------

This announcement is distributed by Thomson Reuters on behalf of Thomson
Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other
applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of
the
information contained therein.

Source: Algeta ASA via Thomson Reuters ONE
HUG#1699177
 
Press spacebar to pause and continue. Press esc to stop.